Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
121.2m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
554.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
283B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
281.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.9B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Verrica Pharmaceuticals Inc
Glance View
Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Verrica Pharmaceuticals Inc is -84.4%, which is above its 3-year median of -701.3%.
Over the last 3 years, Verrica Pharmaceuticals Inc’s Net Margin has increased from -313.6% to -84.4%. During this period, it reached a low of -1 505% on Sep 30, 2023 and a high of -84.4% on Oct 30, 2025.
